Best Life Sciences Companies in Grand Est, France

Developer of wearable sensor devices for monitoring cardiac health. The company is engaged in the development of a lightweight e-health patch MultiSense device that involves the real-time transfer of cardiac and respiratory vital information. The device contains 5 embedded sensors that able to measure vital sign parameters including heart rate, respiratory rate, and oxygen saturation. It uses a proprietary technology that helps to collect chronic information from multiple sensors in an implanted device for evaluation in heart failure patients.

Funding rounds

• Sep 2025Series A$16.6M
• Feb 2021Seed$3.6M

Founders & team

Elie LobelCEO

Investors

Bpifrance, MACSF, Capital Grand Est, Critical Path, SEMIA

Developer of innovative antidepressant treatment, accessible, fast-acting, and free from dependence. It focuses on developing a novel neuroplastogen with a mechanism of action able to induce neuroplasticity without the side effects of psychedelics. The company targets intracellular events and neuroplasticity, acting on a highly selective signaling pathway within neurons in key brain circuits. It is dedicated to advancing psychiatric treatments through precision medicine.

Funding rounds

• Jun 2025Seed$12.8M

Founders & team

Delphine CharvinCEO & Co-Founder & DirectorMelanie RouillierCo-Founder

Investors

Kurma Partners, Angelini Ventures, Wallonie Entreprendre, Argobio, Bpifrance, CARMA FUND

Developer of small molecule drugs for cancer treatment. The company is focusing on developing small molecules targeting the global metabolism of cancer. The company's lead compound, BPR001, is a first-in-class therapeutic targeting BiP, an oncogenic protein involved in ER stress to treat gastrointestinal cancer. Another candidate includes BPR002 for skin cancer.

Funding rounds

• Dec 2025Series A$1.2M
• Feb 2023Grant (prize money)$481.1K
• Feb 2023Seed$855.3K

Founders & team

Rachid BenhidaCo-FounderStephane RocchiCo-FounderCyril RoncoCo-Founder

Investors

WiSEED, Bpifrance, MEDIN Fund Management, SEMIA

Fizimed manufactures a device for controlling urinary leakage. The product Emy is the wireless probe connected to a mobile application. It allows users to do the rehabilitation at home alone. The Emy biofeedback device is used in addition to the perineum reeducation sessions carried out by practitioners and allows patients to continue their exercises at home and practitioners track their work progress.

Funding rounds

• Mar 2025Series A$4.4M

Founders & team

Emeline HahnCo-Founder & CEOAllan MabilaisCo-Founder & CTOPaul GrandemangeCo-Founder

Investors

UI Investissement, UNIQA Group, Bpifrance, Capital Grand Est

Developer of peptide-based therapeutics for cancer. The company's lead product includes AP-01, a cyclic peptide that targets TSP-1 (a ligand of CD47 receptor) in tumor cells. The drug is used to treat glioblastoma, ovarian, colorectal, pancreatic cancer. The company's other drug product includes AP-02 to treat thrombotic disorder. The company has also developed in silico molecular modeling and screening/selection procedure for the validation of drug molecules.

Funding rounds

• Jul 2024Series A$7.6M
• Jul 2024Grant (prize money)$2.7M
• Apr 2024Grant (prize money)$2.9M
• Feb 2022Seed—

Founders & team

Stephane DedieuCo-Founder

Investors

European Innovation Council, Bpifrance, Finovam Gestion, Capitaletcroissance.be

Developer of robotic solution for endovascular access & navigation. The company offers a GECKO System a unique smart handle single-use steerable mechatronic guidewire intended to facilitate the access and positioning of a catheter to reach the obstructing clot.

Funding rounds

• Dec 2023Series A$6.5M
• Jul 2018Grant (prize money)$58.4K
• Feb 2018Grant (prize money)$62.5K

Founders & team

Thierry ColChief Executive Officer - CEO

Investors

Europa, Forepont Capital Partners, Neuro Technology Investors, MedcoEnergi, EIC Fund

Developer of GPCR‑targeted immuno‑oncology and inflammation drug candidates. It offers small molecule and antibody therapeutics targeting G protein‑coupled receptors involved in immune suppression and tumor microenvironment modulation. Its proprietary platform supports the identification and validation of novel GPCR targets. Key programs focus on oral EP4 receptor antagonists for solid tumors, Treg‑depleting anti‑CCR8 antibodies, and PAR2 negative allosteric modulators for inflammatory diseases. The pipeline emphasizes precision therapy guided by biomarker strategies, aiming to enhance immune response and address resistance mechanisms in cancer and inflammation.

Funding rounds

• May 2022Series A$42M
• Jan 2020Conventional Debt$6.7M
• May 2019Series A$3.9M
• Apr 2014Grant (prize money)$230K

Founders & team

Sean MacDonaldCEO

Investors

Banque Populaire, CIC, Caisse D Epargne, Bpifrance, Alsacreations, Auriga Partners

Tech stack

AxeptioCloudflareCloudflare Bot ManagementGoogle AnalyticsMicrosoft 365Mysql

Provider of antisense oligonucleotides for the treatment of rare muscular genetic disorder. Its lead drug program Dyn101 is being developed for the treatment of Centronuclear Myopathies (CNM), a rare muscular genetic disorder. Dyn101 is an antisense oligonucleotide that modulates the expression of the Dynamin 2 protein, developed in collaboration with Ionis Pharmaceuticals. The company was founded as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology-Unistra/INSERM/CNRS) of Strasbourg.

Funding rounds

• Apr 2020Series C$54.8M
• Jul 2018Series A$54.9M

Founders & team

Stephane RooijenCEO

Investors

Perceptive Advisors, Pontifax, Andera Partners, Kurma Partners, Tekla Capital Management, Bpifrance

Developer of cell-based therapies for regenerative medicine. It focuses on developing a bioproduction platform to expand CD34+ cells, known as ProtheraCytes, to promote angiogenesis and revascularization of ischemic lesions. The therapy involves injecting CD34+ cells into patients with severe myocardial infarction to restore normal life and improve long-term cardiac function.

Funding rounds

• Apr 2021Grant (prize money)$6.1M
• May 2018Grant (prize money)$6M
• Jan 2018Grant (prize money)$6M
• Jan 2017Series B$8.8M

Founders & team

Philippe HenonCo-FounderMatthieu KalbermattenCEO

Investors

EIC Fund, Alsace Business Angels, SODIV, Europa, Bpifrance

Tech stack

Apache Http ServerBootstrapChart.JsComplianzContact Form 7Core-Js

Provider of immunotherapy for cancer treatment. The company has patented immunization technology that improves the immune response against the tumor cell. Its technology uses a personalized DNA vector, live poxvirus as an adjuvant, and antiCTLA4 to develop anticancer therapy.

Funding rounds

• May 2023Seed$2.2M
• Feb 2020Seed$1.1M

Founders & team

Jean-Marc LimacherCo-FounderJessica MattaFounder and PartnerPascale BalducchiCEO Odimma-Therapeutics

Investors

Capital Grand Est, Alsace Business Angels, Angels Sante, Bpifrance, SEMIA

Plant biotechnology company producing rare actives for cosmetic, pharmaceutical, agrochemical markets. It extends the frontiers of plant sourcing so that rare compounds can be produced industrially while preserving plant biodiversity. The processes are complete and controlled all the way from the plants to the final product. It focuses on plant biotechnology, vegetal-based chemistry, and metabolic engineering. It collaborates on projects to discover new active molecules of plant origin. The company aims to rationalize and industrialize the discovery and production of very rare plant molecules, offering unmatched perspectives for the detection and exploitation of new plant molecules.

Developer of peptide-based drugs to treat diabetes. The company is developing therapeutics to understand the role of adipocyte cells in diabetes for the management of lipids in the body.